Skip to main content

Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events.

Publication ,  Journal Article
Nallamothu, B; Fox, KAA; Kennelly, BM; Van de Werf, F; Gore, JM; Steg, PG; Granger, CB; Dabbous, OH; Kline-Rogers, E; Eagle, KA; GRACE Investigators,
Published in: Heart
December 2007

OBJECTIVE: Treatment delays may result in different clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) who receive fibrinolytic therapy vs primary percutaneous coronary intervention (PCI). The aim of this analysis was to examine how treatment delays relate to 6-month mortality in reperfusion-treated patients enrolled in the Global Registry of Acute Coronary Events (GRACE). DESIGN: Prospective, observational cohort study. SETTING: 106 hospitals in 14 countries. PATIENTS: 3959 patients who presented with STEMI within 6 h of symptom onset and received reperfusion with either a fibrin-specific fibrinolytic drug or primary PCI. MAIN OUTCOME MEASURES: 6-month mortality. METHODS: Multivariable logistic regression was used to assess the relationship between outcomes and treatment delay separately in each cohort, with time modelled with a quadratic term after adjusting for covariates from the GRACE risk score. RESULTS: A total of 1786 (45.1%) patients received fibrinolytic therapy, and 2173 (54.9%) underwent primary PCI. After multivariable adjustment, longer treatment delays were associated with a higher 6-month mortality in both fibrinolytic therapy and primary PCI patients (p<0.001 for both cohorts). For patients who received fibrinolytic therapy, 6-month mortality increased by 0.30% per 10-min delay in door-to-needle time between 30 and 60 min compared with 0.18% per 10-min delay in door-to-balloon time between 90 and 150 min for patients undergoing primary PCI. CONCLUSIONS: Treatment delays in reperfusion therapy are associated with higher 6-month mortality, but this relationship may be even more critical in patients receiving fibrinolytic therapy.

Duke Scholars

Published In

Heart

DOI

EISSN

1468-201X

Publication Date

December 2007

Volume

93

Issue

12

Start / End Page

1552 / 1555

Location

England

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Thrombolytic Therapy
  • Regression Analysis
  • Prospective Studies
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nallamothu, B., Fox, K. A. A., Kennelly, B. M., Van de Werf, F., Gore, J. M., Steg, P. G., … GRACE Investigators, . (2007). Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. Heart, 93(12), 1552–1555. https://doi.org/10.1136/hrt.2006.112847
Nallamothu, B., K. A. A. Fox, B. M. Kennelly, F. Van de Werf, J. M. Gore, P. G. Steg, C. B. Granger, et al. “Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events.Heart 93, no. 12 (December 2007): 1552–55. https://doi.org/10.1136/hrt.2006.112847.
Nallamothu B, Fox KAA, Kennelly BM, Van de Werf F, Gore JM, Steg PG, Granger CB, Dabbous OH, Kline-Rogers E, Eagle KA, GRACE Investigators. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. Heart. 2007 Dec;93(12):1552–1555.

Published In

Heart

DOI

EISSN

1468-201X

Publication Date

December 2007

Volume

93

Issue

12

Start / End Page

1552 / 1555

Location

England

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Thrombolytic Therapy
  • Regression Analysis
  • Prospective Studies
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Female